VAI’s Process2Clean®, Process Cleaning Detergents, are designed to remove process residues that could contaminate or adulterate further product manufacturing in the pharmaceutical, biotechnology, medical device, and research & development industries.
VAI’s GMP Process2Clean (P2C) cleaning products are specifically formulated for critical process cleaning applications. Each detergent is engineered to effectively remove numerous product residues found in pharmaceutical, biotechnology, medical device, and research & development industries. Process2Clean detergents successfully remove existent residues present in process manufacturing and reduce them down to acceptable trace residual limits. This critical process assures that product contact surfaces are clean prior to subsequent manufacturing and eliminates the possibility of product contamination or product adulteration.
Process2Clean detergents include an Alkaline Detergent, an Acid Based Detergent, a Hydroxyacetic Acid Cleaner, a General Purpose Cleaning Detergent, a Neutral pH Cleaning Additive, and a Chlorinated Alkaline Cleaning Detergent. This complete line of Process2Clean detergents are capable of removing a wide range of residues from inorganic to organic process soils and can be used in numerous cleaning systems from automated to manual.
Process2Clean detergents are formulated with Water for Injection (WFI) and are highly concentrated which translates into low cost per use. All shipments of Process2Clean are delivered with lot specific documentation and are completely validated with an extensive validation support package available. Process2Clean Detergents are available in 1, 5, 30, 55, and 275 gallon options either sterile or non-sterile.
Company name: Veltek Associates, Inc.
Website: www.sterile.com
E-mail: moira.omalley@sterile.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.